Fundamental Analysis of MAGENTA THERAPEUTICS INC(NASDAQ:MGTA) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to MGTA. MGTA was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MGTA as it has an excellent financial health rating, but there are worries on the profitability. MGTA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

MGTA had negative earnings in the past year.

MGTA had a negative operating cash flow in the past year.

MGTA had negative earnings in each of the past 5 years.

MGTA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for MGTA are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MGTA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for MGTA has been increased compared to 1 year ago.

Compared to 5 years ago, MGTA has less shares outstanding

There is no outstanding debt for MGTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -8.66, we must say that MGTA is in the distress zone and has some risk of bankruptcy.

MGTA has a worse Altman-Z score (-8.66) than 77.59% of its industry peers.

MGTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-8.66

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 19.49 indicates that MGTA has no problem at all paying its short term obligations.

The Current ratio of MGTA (19.49) is better than 93.08% of its industry peers.

MGTA has a Quick Ratio of 19.49. This indicates that MGTA is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 19.49, MGTA belongs to the best of the industry, outperforming 93.08% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	19.49
Quick Ratio	19.49

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.98% over the past year.

EPS 1Y (TTM)12.98%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q82.76%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

MGTA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.46% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y34.37%

EPS Next 2Y41.98%

EPS Next 3Y26.32%

EPS Next 5Y6.46%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGTA. In the last year negative earnings were reported.

The Price/Forward Earnings ratio is 34.29, which means the current valuation is very expensive for MGTA.

Based on the Price/Forward Earnings ratio, MGTA is valued cheaply inside the industry as 94.73% of the companies are valued more expensively.

MGTA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.88.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	34.29

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MGTA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as MGTA's earnings are expected to grow with 26.32% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.98%

EPS Next 3Y26.32%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MGTA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MAGENTA THERAPEUTICS INC

NASDAQ:MGTA (9/11/2023, 7:06:21 PM)

0.6996

-0.06 (-7.74%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.65M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	34.29
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	19.49
Quick Ratio	19.49
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)12.98%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y34.37%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MAGENTA THERAPEUTICS INC (MGTA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens